Ensysce Biosciences Receives $14M Multi-Year Grant From NIH For Continued Development Of PF614-MPAR Abuse-Deterrent Opioid With Overdose Protection
Portfolio Pulse from Benzinga Newsdesk
Ensysce Biosciences has been awarded a $14 million multi-year grant from the NIH to further develop its PF614-MPAR, an abuse-deterrent opioid with overdose protection. This funding will support the continued research and development of this innovative drug.
August 27, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ensysce Biosciences received a $14M grant from the NIH to develop PF614-MPAR, an abuse-deterrent opioid. This funding is crucial for advancing their R&D and could positively impact their financials and stock price.
The $14M grant from the NIH is a significant financial boost for Ensysce Biosciences, enabling them to continue developing their innovative opioid product. This could lead to advancements in their product pipeline and potentially increase investor confidence, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100